Center-Authored Papers

Filters: Author is Hamlin, Don K  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Subbiah K, Hamlin DK, Pagel JM, Wilbur SD, Meyer DL, Axworthy DB, Mallett RW, Theodore LJ, Stayton PS, Press OW.  2003.  Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 44(3):437-45. Abstract
P
Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur SD, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T et al..  2010.  Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.. Blood. 116(20):4231-9. Abstract
Pagel JM, Lin Y, Hedin N, Pantelias A, Axworthy D, Stone D, Hamlin DK, Wilbur SD, Press OW.  2006.  Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.. Blood. 108(1):328-36. Abstract
H
Hamblett KJ, Press OW, Meyer DL, Hamlin DK, Axworthy D, Wilbur SD, Stayton PS.  2005.  Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.. Bioconjugate chemistry. 16(1):131-8. Abstract
Hamblett KJ, Kegley BB, Hamlin DK, Chyan M-K, Hyre DE, Press OW, Wilbur SD, Stayton PS.  2002.  A streptavidin-biotin binding system that minimizes blocking by endogenous biotin.. Bioconjugate chemistry. 13(3):588-98. Abstract